Novocure Appoints Company President Frank Leonard as Chief Executive Officer

BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. “During his more than 15-year career at Novocure, Frank has led many of our global business operations developing deep expertise in delivering our unique, device-based cancer therapy to patients to extend their surv.

Business Wire • Dec 1, 2025

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle, Novocure's Executive Chairman, will take part in a fireside chat at 11:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure's website, www.novocure.c.

Business Wire • Nov 26, 2025

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer, will present on behalf of the company at 2:00 p.m. GMT (9:00 a.m. ET). Ms. Cordova will be joined by Christoph Brackmann, Chief Financial Officer, for one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be acc.

Business Wire • Nov 12, 2025

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon

A biotech upstart and a life sciences giant could be compelling additions to an investor's portfolio. NovoCure is a high-risk but potentially high-reward bet on industry-changing technology.

The Motley Fool • Nov 12, 2025

NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript

NovoCure Limited ( NVCR ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Ingrid Goldberg - VP of Investor Relations William Doyle - Executive Chairman Ashley Cordova - CEO & Director Christoph Brackmann - Chief Financial Officer Frank Leonard - President Conference Call Participants Jason Bednar - Piper Sandler & Co., Research Division Kevin Joaquin - Evercore ISI Institutional Equities, Research Division Tanmay Patwardhan Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.

Seeking Alpha • Oct 30, 2025

Novocure Reports Third Quarter 2025 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Q3 was a solid quarter with steady commercial execution in glioblastoma, geographic expansion, and material progress for our clinical and product de.

Business Wire • Oct 30, 2025

Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics

The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Oct 30, 2025

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.28 per share a year ago.

Zacks Investment Research • Oct 30, 2025

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum

Novocure Limited (NVCR) is rated BUY, driven by expanding regulatory approvals, breakthrough clinical results, and a robust late-stage pipeline in cancer therapy. NVCR's Tumor Treating Fields technology offers a differentiated, device-based approach to cancer treatment, with recent milestones in glioblastoma, lung, and pancreatic cancers. Upcoming Q3 results and regulatory updates, including METIS and PANOVA-3, are key catalysts, supported by strong liquidity and cautious financial management.

Seeking Alpha • Oct 17, 2025

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague, Czech Republic, and the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. At the EANO 2025 Meeting, Novocure will present pre-clinical data highlighting the potential of Tumor Treating Fields (TTFields) th.

Business Wire • Oct 15, 2025